October 2023 in “IP Indian Journal of Clinical and Experimental Dermatology” The luliconazole shampoo effectively reduces symptoms of seborrheic dermatitis and is well-tolerated.
2 citations
,
February 2022 in “Preprints.org” Fermented red ginseng marc may help treat atopic dermatitis by reducing inflammation and improving skin health.
November 2022 in “Chinese Journal of Dermatology” Allergies, especially dust mite allergy, may worsen alopecia areata, and desensitization could help reduce its severity.
1 citations
,
June 2017 in “Skin” Apremilast may help treat lichen planopilaris and frontal fibrosing alopecia when other treatments fail.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
December 2013 in “Cumhuriyet Tıp Dergisi/Cumhuriyet Üniversitesi Tıp Fakültesi dergisi” Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.
26 citations
,
May 1991 in “Clinical and experimental dermatology” Oral etretinate improved hair length and reduced beading in monilethrix.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
1 citations
,
May 2023 in “The Journal of Dermatology” Allergen-specific immunotherapy can significantly improve hair loss and dermatitis symptoms in severe cases.
January 2017 in “Postepy Dermatologii I Alergologii” The CRH/CRH-R1 system might be involved in causing lichen planus.
January 2023 in “Figshare” Triple therapy with clobetasol, hydroxychloroquine, and N-acetylcysteine is recommended for better outcomes in treating lichen planopilaris.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
May 2008 in “10th European Congress of Endocrinology” July 2024 in “Journal of Investigative Dermatology”
1 citations
,
November 2023 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib helps with early hair regrowth in people with alopecia areata.
September 2024 in “Polish Journal of Public Health” Prescription tablets treat hirsutism, while over-the-counter foams treat hypertrichosis.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
January 2023 in “Revista Brasileira de Parasitologia Veterinária/Brazilian Journal of Veterinary Parasitology” A single dose of fluralaner effectively treats mite infestations in cats without side effects.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
5 citations
,
July 2003 in “Annals of the Rheumatic Diseases” An antibiotic called co-trimoxazole can effectively treat autoimmune diseases.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
March 2026 in “SKIN The Journal of Cutaneous Medicine” All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.
May 2018 in “Dermatologic Surgery”
March 2026 in “American Journal of Clinical Dermatology” 3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.